CJC-1295 + Ipamorelin: What the Research Shows About the Growth-Hormone-Axis Blend

A research overview of the CJC-1295 + Ipamorelin blend: the GHRH analog and selective GH secretagogue, what published research examined, and lab handling. For research use only.

The CJC-1295 + Ipamorelin blend pairs two peptides frequently studied together in growth-hormone-axis research. This guide summarizes what the published scientific literature has examined about each component, their molecular profiles, and how the blend is handled in a research setting. It is written for researchers and is not medical guidance.

What is the CJC-1295 + Ipamorelin blend?

This is a two-component research blend:

  • CJC-1295 (without DAC) — a synthetic analog of growth-hormone-releasing hormone (GHRH) studied for its activity at the GHRH receptor.
  • Ipamorelin (CAS 170851-70-4; molecular formula C38H49N9O5; molar mass ≈ 711.9 g/mol) — a selective growth-hormone secretagogue and ghrelin-receptor agonist.

Research-use note: This blend is supplied strictly for laboratory research. It is not an approved drug or supplement and is not for human or animal consumption. Findings below come from published research studies.

How the blend works (the mechanism studied)

The two peptides act on complementary pathways of growth-hormone regulation. CJC-1295 is studied as a GHRH-receptor agonist, while ipamorelin is studied as a selective secretagogue acting at the ghrelin/GH-secretagogue receptor. Researchers have examined each pathway for its influence on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in study models — which is why the two are commonly combined in research protocols.

What researchers have studied

  • CJC-1295 — Teichman et al. (J Clin Endocrinol Metab, 2006) examined prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults.
  • Ipamorelin — Raun et al. (European Journal of Endocrinology, 1998) characterized ipamorelin as the first selective growth-hormone secretagogue.

These findings belong to the published research record and do not represent approved or validated uses of the research compounds sold here. See also our tesamorelin research guide on a related GHRH analog.

Handling and reconstitution in the laboratory

The blend is typically supplied as a lyophilized powder for research use. Standard laboratory practice is to reconstitute it with bacteriostatic water, swirl (not shake) until dissolved, and store the reconstituted solution refrigerated (2–8 °C). The lyophilized powder is generally stored frozen and protected from light. (General lab-handling notes, not usage instructions.)

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice.

Explore this blend and related research peptides

References

  1. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed